Structure Therapeutics (GPCR)
International Stocks
Buy
CEO Ray Stevens analyzes the company's obesity drug portfolio, cash position, and merger (M&A) rumors in the sector.
Ray Stevens93d
* Does not constitute investment advice
Yükleniyor...
Yükleniyor...
How recommendation distribution changed over time
Covered by 5 analysts
Mixed views among analysts
Last evaluation 93+ days ago - stale data
Both buy and sell recommendations exist
Decreasing interest recently
Chronological view of analyst recommendations for this asset
CEO Ray Stevens analyzes the company's obesity drug portfolio, cash position, and merger (M&A) rumors in the sector.
CNBC TelevisionThe speaker evaluates the potential of the company's oral GLP-1 drug and its competitive status against sector leader Eli Lilly.
CNBC TelevisionThe speaker acknowledges the legitimacy of the company's deal with Roche but remains distant, preferring larger and established competitors in the sector.
CNBC TelevisionThe speaker examines the strategic position in the biotech sector and potential corporate merger scenarios.
CNBC TelevisionThe speaker examines the high standards and clinical trial processes faced by smaller players in the sector.
CNBC TelevisionThe speaker evaluates Structure Therapeutics among companies with high dealmaking potential in the biotech space.
CNBC TelevisionThe analyst analyzes the company's recent clinical data release and merger/acquisition potential in the sector.
CNBC TelevisionThe strategist highlights Structure Therapeutics as a company of interest for investors, analyzing its potential role in the obesity market following recent data.
CNBC TelevisionCEO Ray Stevens analyzes the company's obesity drug portfolio, cash position, and merger (M&A) rumors in the sector.
* Does not constitute investment advice
The speaker evaluates the potential of the company's oral GLP-1 drug and its competitive status against sector leader Eli Lilly.
* Does not constitute investment advice
The speaker acknowledges the legitimacy of the company's deal with Roche but remains distant, preferring larger and established competitors in the sector.
* Does not constitute investment advice
The speaker examines the strategic position in the biotech sector and potential corporate merger scenarios.
* Does not constitute investment advice
The speaker examines the high standards and clinical trial processes faced by smaller players in the sector.
* Does not constitute investment advice
The speaker evaluates Structure Therapeutics among companies with high dealmaking potential in the biotech space.
* Does not constitute investment advice
The analyst analyzes the company's recent clinical data release and merger/acquisition potential in the sector.
* Does not constitute investment advice
The strategist highlights Structure Therapeutics as a company of interest for investors, analyzing its potential role in the obesity market following recent data.
* Does not constitute investment advice